Want to see HK:6185 full AI Analyst Report?
6185 Stock Chart & Stats
HK$44.94
-HK$0.10(-0.36%)
At close: 4:00 PM EST
HK$44.94
-HK$0.10(-0.36%)
Day’s Range― - ―
52-Week RangeHK$19.22 - HK$53.45
Previous CloseN/A
Volume470.05K
Average Volume (3M)8.29M
Market Cap
HK$14.57B
Enterprise ValueHK$4.51K
Total Cash (Recent Filing)HK$1.84B
Total Debt (Recent Filing)HK$979.87M
Price to Earnings (P/E)434.7
Beta1.59
Next Earnings
Nov 02, 2026EPS Estimate
0.3Next Dividend Ex-DateN/A
Dividend Yield1.31%
Share Statistics
EPS (TTM)0.16
Shares Outstanding132,670,900
10 Day Avg. Volume4,916,176
30 Day Avg. Volume8,286,040
Financial Highlights & Ratios
PEG Ratio-2.66
Price to Book (P/B)1.60
Price to Sales (P/S)7.70
P/FCF Ratio-52.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$50.53Price Target Upside12.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.39
Revenue Forecast (FY)HK$1.44B
Bulls Say, Bears Say
Bulls Say
Integrated Vaccine CapabilitiesAn end-to-end vaccine platform gives CanSino control across development, regulatory execution, manufacturing, and commercialization. This integrated capability can support product launches, improve coordination between functions, and create a durable base for serving domestic and international markets over multiple quarters.
Revenue Growth And Gross MarginRevenue growth alongside a strong gross margin indicates that commercial activity is improving while vaccine products retain substantial contribution after direct costs. If maintained, this combination can provide resources for research, regulatory work, and commercialization as the portfolio develops.
Moderate LeverageModerate and improving leverage provides a relatively supportive capital structure for a biotechnology company still investing in its pipeline. A sizable equity base can preserve financial flexibility for development and production needs, reducing balance-sheet pressure as profitability recovers.
Bears Say
Negative Free Cash FlowMeaningfully negative free cash flow shows that CanSino is still consuming cash after investment spending, despite positive operating cash flow. Continued cash burn can constrain internal funding for vaccine development and capacity, making sustained liquidity and financing flexibility important over the medium term.
Fragile ProfitabilitySlightly negative operating profit and near-breakeven net results indicate that revenue growth has not yet translated into durable earnings power. The sharp swings from large 2021 profits to heavy losses in 2022–2024 also reduce confidence that margins and profitability will remain consistent.
Low Return On EquityLow return on equity suggests the company is not yet converting its substantial capital base into strong, consistent shareholder returns. Until operating profitability improves, this weak capital productivity may limit the effectiveness of retained resources and indicate that recovery remains incomplete.
CanSino Biologics, Inc. Class H News
6185 FAQ
What was CanSino Biologics, Inc. Class H’s price range in the past 12 months?
CanSino Biologics, Inc. Class H lowest stock price was HK$19.22 and its highest was HK$53.45 in the past 12 months.
What is CanSino Biologics, Inc. Class H’s market cap?
CanSino Biologics, Inc. Class H’s market cap is HK$14.57B.
When is CanSino Biologics, Inc. Class H’s upcoming earnings report date?
CanSino Biologics, Inc. Class H’s upcoming earnings report date is Nov 02, 2026 which is in 39 days.
How were CanSino Biologics, Inc. Class H’s earnings last quarter?
CanSino Biologics, Inc. Class H released its earnings results on Aug 27, 2026. The company reported HK$0.187 earnings per share for the quarter, missing the consensus estimate of HK$0.24 by -HK$0.053.
Is CanSino Biologics, Inc. Class H overvalued?
According to Wall Street analysts CanSino Biologics, Inc. Class H’s price is currently Undervalued.
Does CanSino Biologics, Inc. Class H pay dividends?
CanSino Biologics, Inc. Class H pays a Notavailable dividend of HK$0.937 which represents an annual dividend yield of 1.31%. See more information on CanSino Biologics, Inc. Class H dividends here
What is CanSino Biologics, Inc. Class H’s EPS estimate?
CanSino Biologics, Inc. Class H’s EPS estimate is 0.3.
How many shares outstanding does CanSino Biologics, Inc. Class H have?
CanSino Biologics, Inc. Class H has 132,670,900 shares outstanding.
What happened to CanSino Biologics, Inc. Class H’s price movement after its last earnings report?
CanSino Biologics, Inc. Class H reported an EPS of HK$0.187 in its last earnings report, missing expectations of HK$0.24. Following the earnings report the stock price went down -1.345%.
Which hedge fund is a major shareholder of CanSino Biologics, Inc. Class H?
Currently, no hedge funds are holding shares in HK:6185
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CanSino Biologics, Inc. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.47%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CanSino Biologics, Inc. Class H
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.
6185 Stock 12 Month Forecast
Average Price Target
HK$50.53
▲(12.45% Upside)
Technical Analysis
HUTCHMED (China)
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Ab&B Bio-Tech CO., LTD. JS Class H
―
Xuanzhu Biopharmaceutical Co., Ltd. Class H
―